logo-loader
Instem PLC

Instem secures US$750,000 contract with Fortune 500 heavyweight

Phil Reason, chief executive of Instem Plc (LON:INS), tells Proactive Investors a Fortune 500 medical products and pharma company has adopted its Samarind Regulatory Management System.

The deal is worth an initial US$750,000, with 80% of that sum being recognised this year, and brings with it recurring annual revenues of US$169,000.

Quick facts: Instem PLC

Price: £3.82

Market: AIM
Market Cap: £62.26 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Instem PLC named herein, including the promotion by the Company of Instem PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

SEND platform the star first-half performer for Instem PLC

Phil Reason, chief executive of Instem Plc (LON:INS), caught up with Proactive to discuss their first-half 2018 trading update. He says trading's been in line with expectations with the standout performer being their SEND platform where the value of contracts won so far this year has...

on 24/7/18

2 min read